Metabolic-disease CRO poised for growth
With an infusion of capital from investors 1315 Capital, ProSciento is setting its sights on expansion of its specialized clinical research services.
With an infusion of capital from investors 1315 Capital, ProSciento is setting its sights on expansion of its specialized clinical research services.
The companies are partnering to help expand much-needed access to decentralized clinical trials for central nervous system patients and caregivers.
The latest analytical report from Life Science Strategy Group reveals position and perception of the leading players and performers in the eClinical arena.
Mission Bio has launched a tool it claims will help save the industry billions of dollars in drug development costs and bring life-saving treatments to market at least six months faster.